Articles tagged with Pancreatic Cancer
Researchers at OHSU found that sympathetic nerves support pancreatic tumor growth by communicating with cancer cells and nearby fibroblasts. The study suggests that removing these nerves may lead to smaller tumors, particularly in female mice.
Researchers identified a key gene GATA6 that helps control the 'switch' between aggressive and manageable states in pancreatic cancer cells. By targeting this pathway, combination therapies with standard chemotherapy may improve treatment outcomes.
Researchers found that early precancerous cells in pancreas gather into specific clusters and interact with immune cells, weakening the body's ability to fight them. The study provides fresh insight into how pancreatic cancer may begin taking shape years before it is clinically detected.
A new study analyzing 519 patients with cancer reveals that financial toxicity significantly impacts not only finances but also psychological resources like hope and social support. As these resources weaken, overall life satisfaction declines.
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
Cancer cell researchers at the University of Oklahoma have developed a novel 'triangle regulation theory' that explains the development of cancer-induced cachexia and anorexia. The theory reveals how cancer cells recruit immune cells to trigger excess production of growth factor 15, leading to muscle wasting and loss of appetite.
Researchers found that an experimental compound SB-216 reduced the growth of pancreatic ductal adenocarcinoma cells by inhibiting oncogenic microtubules and mitochondrial function. This approach may reduce cancer cell adaptation and survival.
A study published in Molecular Cancer found that the KLF5 gene plays a crucial role in fueling the growth of spreading pancreatic cancer by altering epigenetic changes. The researchers used CRISPR technology to silence genes and identified KLF5 as the most impactful gene associated with cell growth.
Researchers found that when pancreatic tumors touch the superior mesenteric vein, patients who undergo surgery first experience reduced survival rates. In contrast, those who receive chemotherapy before surgery have similar survival outcomes to those with non-vein touching tumors. The study suggests reclassifying tumors based on vein i...
Scientists found that tumor-promoting fibroblasts attract nerve fibers through a vicious cycle of signaling and neurotransmitter release. This cycle promotes pre-cancerous growth and pulls in more nerve fibers, leading to a self-reinforcing loop. Disrupting this cycle may lead to new therapies for pancreatic cancer.
Researchers from Memorial Sloan Kettering Cancer Center reveal the origins of Thetis cells, which play a crucial role in teaching immune system tolerance. The team used single-nucleus DNA sequencing to shed light on pancreatic cancer evolution and identify genetic changes that occur earlier or later in disease progression.
A new study reveals that the surrounding microenvironment plays a crucial role in driving basal cell development, leading to treatment failure. The study also discovers intermediate tumor subtypes that could lead to new therapeutic strategies.
A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers have developed a four-marker panel that can detect early-stage pancreatic cancer with high accuracy, potentially improving survival rates. The new test distinguishes cancer patients from healthy individuals and those with non-cancerous conditions, such as pancreatitis.
A four-biomarker blood panel including aminopeptidase N, polymeric immunoglobulin receptor, and thrombospondin-2 has been shown to enhance the detection of pancreatic ductal adenocarcinoma compared to CA19-9 alone. The panel correctly detected 91.9% of pancreatic cancers across all stages.
Cancer researchers have identified a key mechanism by which cancer cells protect themselves from the immune system. The study found that MYC protein can bind to RNA molecules, eliminating alarm signals that would activate the immune defense.
A study led by Aaron Hobbs and Rachel Burge reveals the distinct cell signaling and tumor microenvironment behind a slower-growing pancreatic tumor mutation. G12R KRAS mutations lead to better patient outcomes, including earlier diagnoses and longer survival times.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
Pancreatic cancer cells use specific microRNA molecules to reprogram nearby immune cells called macrophages, helping tumors grow. By blocking this communication, researchers found a potential way to reverse the process and restore macrophage function to fight cancer.
The study reveals that low levels of CTDNEP1 drive early and deadly pancreatic tumors, highlighting its role as a tumor suppressor. Tumors with low CTDNEP1 expression showed stronger metabolic activity and immune evasion.
A new study by CNIO has identified two genes in the complement system that increase the risk of pancreatic ductal adenocarcinoma. These genes, FCN1 and PLAT, may serve as biomarkers for screening high-risk populations.
A new consensus classifier for pancreatic cancer has been developed, enabling accurate determination of tumor subtypes and informing treatment choices. The tool also identifies risk factors for the disease, including smoking, which may be more significant in certain subtypes.
Researchers have discovered a complex regulatory circuit involving SRSF1, AURKA, and MYC that promotes aggressive pancreatic cancer progression. The circuit, which involves alternative splicing, can be targeted with an antisense oligonucleotide to reduce tumor cells' viability and trigger apoptosis.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
A systematic review found that pancreatic cancer surgery significantly increases the risk of new-onset diabetes mellitus (NODM), particularly in patients with known risk factors. The study analyzed 45 studies and found an overall incidence of NODM of 24.5%, with a higher rate in those who underwent distal pancreatectomy.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers developed a 13-point risk score to predict PanNET recurrence, based on male sex, tumor size, WHO grade, and lymphovascular invasion. The tool will help physicians identify high-risk patients for closer monitoring.
Researchers at IIT identified a candidate molecule called Apt1 that enhances existing anticancer therapies by making tumour cells more vulnerable to chemotherapy drugs. The molecule slows DNA repair and impairs the interaction between RAD51 and BRCA2 proteins, inducing synthetic lethality in cancerous cells.
Researchers at the University of Houston have discovered a potential therapeutic strategy for counteracting muscle wasting in pancreatic cancer by blocking a specific cell pathway. Muscle wasting, also known as cachexia, is a debilitating syndrome affecting 60-85% of patients with pancreatic cancer.
Researchers at UT Health San Antonio successfully used radiofrequency ablation to treat a patient with pancreatic cancer, achieving the first-ever less-invasive procedure in South Texas. The treatment has shown promising results in shrinking tumors and easing symptoms, potentially improving patient outcomes.
Researchers from Okayama University and Tohoku University have identified a promising way to breach the physical and biochemical barrier created by fibrosis in pancreatic cancer. By blocking collagen signaling through DDR1, they improve drug delivery and enhance treatment response.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
Researchers have identified critical cellular targets to improve pancreatic tumor sensitivity to KRAS inhibitors. The team found that certain patient populations may preferentially respond to anti-KRAS and anti-EGFR combination therapies.
Cancer researchers at Cold Spring Harbor Laboratory have identified key proteins that determine the behavior of two hard-to-treat carcinomas, pancreatic cancer and tuft cell lung cancer. These findings could lead to new therapies targeting specific vulnerabilities in these cancers.
A new study using magnetoelectric nanoparticles successfully shrinks pancreatic tumors in preclinical models, extending survival. The Sylvester Cancer Institute has also launched its Survivorship and Supportive Care Institute to provide evidence-based care for cancer patients.
A nationwide telehealth clinical trial is now open at Ohio State University Wexner Medical Center for adults with advanced or metastatic pancreatic cancer with specific mutations in the fibroblast growth factor receptor (FGFR) gene. The study will test pemigatinib, a smart drug targeting these genetic mutations.
Researchers developed an RNA-based therapeutic strategy targeting mutant KRAS genes, stimulating the immune system to attack tumours. The treatment, combining antisense oligonucleotides and immunomodulatory RNA, effectively killed cancer cells in laboratory studies, reducing tumour burden and extending survival.
Researchers at University of Illinois Chicago have developed a microfluidic device that can isolate pancreatic cancer cells from blood samples with high accuracy. The lidocaine infusion method has shown promise in reducing the aggressiveness of circulating tumor cells and may help lower the risk of metastasis.
Researchers at UC Riverside and City of Hope have developed a novel Pin1 degrading compound that suppresses pancreatic cancer peritoneal metastases. The treatment targets not only cancer cells but also tumor-supporting cells, potentially overcoming treatment resistance.
Researchers identified mild dilatation of the pancreatic duct as an early sign of pancreatic cancer in high-risk individuals, even without visible mass. This finding may lead to better survival rates if cancers are detected early through more frequent imaging.
Researchers discovered that pancreatic tumors form pseudosynapses, exploiting the body's nervous system to drive tumor growth. Calcium waves triggered by glutamate binding promote metastasis and cancer progression.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
Researchers developed nanomachines that can function stably within living organisms, enabling starvation therapy to treat refractory pancreatic cancer. This approach improved treatment outcomes by depleting essential nutrients for cancer cell growth.
A new study found that magnetoelectric nanoparticles can locate and destroy pancreatic tumors in preclinical models, reducing tumor size by one-third and extending survival time. The treatment uses no drugs or invasive procedures, instead guiding the nanoparticles to the tumor site using a small magnet and activating them with an MRI s...
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
A rare case of pancreatic Hodgkin lymphoma was reported, emphasizing the need for tissue diagnosis before definitive treatment. The patient's symptoms and imaging findings initially raised concern for pancreatic adenocarcinoma, but a biopsy revealed nodular sclerosis subtype of Hodgkin lymphoma.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
Researchers at the University of Cincinnati Cancer Center have developed a new drug targeting Hsp70, a key protein aiding tumor resistance, reducing tumor size and increasing survival in animal models.
Researchers discovered that blocking two key proteins, Ref-1 and PRDX1, significantly shrunk tumors and increased cancer cell death. The approach also affected the tumor's surrounding environment, highlighting its effectiveness in disrupting the tumor's support system.
Researchers identified 27 species of bacteria and fungi that collectively increase the risk of pancreatic cancer by 3.5 times. The study analyzed saliva samples from 122,000 healthy individuals and found that boosting the mouth's microbiome may protect against cancer.
A cohort study reveals oral bacteria and fungi as significant risk factors for pancreatic cancer development. The findings suggest that oral microbiota may serve as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention strategies.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.